All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
⭐MPN Hub spotlight: The ROP-ET trial of ropeginterferon alfa-2b in patients with ET and limited treatment options ⭐
Ropeginterferon alfa-2b, an interferon-based therapy, has demonstrated robust hematologic efficacy and sustained molecular response in patients with polycythemia vera and is commonly used off-label for the treatment of patients with essential thrombocytosis with high overall response rates and myelofibrosis-free survival.
The ongoing, prospective, multicenter phase III ROP-ET study will assess the efficacy and safety of ropeginterferon alfa-2b in patients with essential thrombocytosis with limited treatment options.
This educational resource is independently supported by AOP Orphan. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
- Rumi E, Cazzola M. How I treat essential thrombocythemia. Blood. 2016;128(20):2403-2414. DOI: 10.1182/blood-2016-05-643346
- Kiladjian JJ, et al. ROP-ET: A prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Abstract #634. 65th ASH Annual Meeting and Exposition; Dec 9–12, 2024; San Diego, US.
- Vachhani P, Mascarenhas J, Bose P, et al. Interferons in the treatment of myeloproliferative neoplasms, Ther Adv Hematol. 2024;15:20406207241229588. DOI: 10.1177/20406207241229588
- Kiladjian JJ, Marin FF, Al-Ali HK, et al. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Ann Hematol. 2024;103(7):2299-2310. DOI: 10.1007/s00277-024-05665-4